RN
Cartesian Therapeutics, Inc.
RNAC · NASDAQ
$8.08 +0.25% (+$0.02)
1M -19.68%
Market Cap $237.4M
P/E Ratio -
Div. Yield -
ROE -
Piotroski F-Score Weak
2/9Valuation
0 /100
Expensive P/S 160.73x
PEG N/A
P/E N/A
Growth
0 /100
Declining Rev. growth 70.66%
Book val. growth N/A
EPS growth N/A
Profitability
0 /100
Weak Op. margin 6,679.69%
Gross margin 766.42%
FCF margin 5,291.54%
Quality
0 /100
Poor Asset turnover 0.00x
ROIC 30.78%
ROA 48.31%
Debt
43 /100
Moderate Int. coverage -188.07x
Current ratio 7.48x
Debt/Assets N/A
Stability
26 /100
Unstable EPS volatility 1,029.74%
Beta 0.62x
Profitable years 0
Bulios Scoring descrie calitatea și istoricul unei companii, nu randamentul viitor. Un scor ridicat nu este un semnal de cumpărare. Află mai multe
Întreabă StockBot despre RNAC
Online
Sector
Healthcare
Industry
Biotechnology
CEO
Carsten Brunn
Employees
75
Headquarters
Frederick
Evenimente viitoare
05 NOV.
Earnings
Upcoming earnings report